menu
    • menu
    [{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"NIH","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human iPSC-derived cardiac tissues","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"NanoSurface Biomedical \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ NIH"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RedHill Biopharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opaganib

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : Duke University School

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RedHill Collaborates with U.S. Academic Center on Opaganib for Phosgene Injury

                            Details : The collaboration is designed to test ABC294640 (opaganib), a first-in-class, orally administered SPHK2 selective inhibitor, as a potential medical countermeasure to treat phosgene inhalation injury.

                            Brand Name : Yeliva

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : Opaganib

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : Duke University School

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NanoSurface Biomedical

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            NanoSurface Biomedical

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human iPSC-derived cardiac tissues

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : NIH

                            Deal Size : $4.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NanoSurface Biomedical Awarded $1.9M in Funding from NIH

                            Details : The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 03, 2020

                            Lead Product(s) : Human iPSC-derived cardiac tissues

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : NIH

                            Deal Size : $4.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth